lebanon
author
contribut
equal
work
word
count
abstract
word
main
text
word
number
figur
number
tabl
run
head
vaccin
impact
abstract
background
sever
vaccin
candid
current
pipelin
studi
aim
inform
vaccin
develop
licensur
decisionmak
implement
determin
key
prefer
vaccin
product
characterist
associ
populationlevel
impact
method
vaccin
impact
assess
variou
efficaci
use
agestructur
mathemat
model
describ
transmiss
diseas
progress
applic
china
result
prophylact
vaccin
efficaci
acquisit
need
elimin
infect
vaccin
still
major
impact
may
control
infect
reduc
infecti
infect
durat
among
vaccin
acquir
infect
altern
supplement
moder
socialdistanc
intervent
reduct
contact
rate
complement
herd
immun
vaccin
costeffect
vaccin
number
vaccin
need
avert
one
infect
one
sever
diseas
case
one
critic
diseas
case
one
death
gain
effect
achiev
initi
priorit
year
probabl
major
outbreak
virtual
zero
vaccin
regardless
number
viru
introduct
yet
increas
social
contact
rate
among
vaccin
behavior
compens
undermin
vaccin
impact
conclus
even
partiallyefficaci
vaccin
offer
fundament
solut
control
infect
high
costeffect
addit
primari
endpoint
infect
acquisit
develop
assess
natur
histori
diseas
progress
outcom
right
reserv
reus
allow
without
permiss
follow
sever
acut
respiratori
syndrom
sar
epidem
middl
east
respiratori
syndrom
mer
epidem
novel
coronaviru
sever
acut
respiratori
syndrom
coronaviru
emerg
late
decemb
wuhan
hubei
provinc
china
earlier
coronaviru
epidem
rather
limit
scope
scale
rapidli
spread
evolv
pandem
absenc
vaccin
even
partial
efficaci
contain
epidem
china
necessit
largescal
contact
trace
test
deploy
thousand
healthcar
fieldwork
along
sever
quarantin
measur
strain
put
healthcar
system
global
human
econom
loss
caus
viru
result
diseas
design
coronaviru
diseas
acceler
effort
toward
vaccin
develop
multipl
vaccin
candid
current
pipelin
still
earli
stage
develop
assess
populationlevel
impact
vaccin
candid
mathemat
model
critic
compon
process
vaccin
develop
valu
proposit
licensur
decisionmak
pathway
cost
vaccin
administr
util
wide
rang
infecti
diseas
earli
stage
develop
model
use
defin
vaccin
key
prefer
product
characterist
estim
level
efficaci
necessari
observ
signific
populationlevel
impact
determin
necessari
durat
protectionimmun
incur
vaccin
identifi
prioriti
popul
optim
effect
paramet
provid
earli
guidanc
develop
manufactur
regul
decis
maker
candid
like
optim
specifi
vaccin
characterist
maxim
public
health
impact
costeffect
key
attribut
establish
model
play
integr
role
build
case
invest
vaccin
develop
ensur
rapid
rollout
postlicens
assess
risk
cost
predict
return
associ
differ
immun
strategi
postvaccin
model
use
inform
design
interpret
surveil
studi
aim
studi
provid
scientif
evid
necessari
inform
acceler
vaccin
develop
licensur
decisionmak
implement
determin
key
prefer
vaccin
product
characterist
associ
populationlevel
impact
critic
time
develop
vaccin
unvaccin
popul
nine
age
group
consid
repres
age
band
except
last
categori
year
suscept
individu
risk
expos
infect
vari
hazard
rate
depend
age
group
vaccin
statu
follow
latenc
period
infect
individu
develop
asymptomat
mild
infect
follow
recoveri
sever
infect
follow
sever
diseas
recoveri
critic
infect
follow
critic
diseas
either
recoveri
diseas
mortal
mix
individu
differ
age
group
determin
age
mix
matrix
allow
rang
mix
detail
model
structur
sm
model
code
fit
analys
use
matlab
model
parameter
calibr
use
empir
data
natur
histori
epidemiolog
agespecif
distribut
infect
individu
across
mild
sever
critic
infect
stage
base
casesever
level
observ
china
critic
diseas
case
risk
diseas
mortal
rel
mortal
rate
age
group
inform
agespecif
crude
case
fatal
rate
observ
china
tabl
section
b
sm
assess
impact
prophylact
vaccin
reduc
suscept
infect
howev
sinc
first
avail
vaccin
may
partial
efficaci
infect
acquisit
also
assess
impact
vaccin
assum
addit
breakthrough
effect
effect
modul
natur
histori
infect
vaccin
still
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
acquir
infect
specif
assum
vaccin
may
reduc
infecti
per
one
contact
reduc
viral
load
infect
durat
faster
clearanc
vaccineinduc
immun
likelihood
develop
sever
critic
diseas
rapid
immun
respons
prevent
diseas
progress
definit
vaccin
efficaci
summar
tabl
relev
characterist
includ
durat
protect
elicit
vaccin
vaccin
effect
adher
social
distancingw
investig
impact
increas
social
contact
rate
follow
vaccin
percept
protect
populationlevel
impact
vaccin
assess
quantifi
incid
cumul
incid
reduct
incid
infect
sever
diseas
case
critic
diseas
case
death
aris
presenc
vaccin
compar
counterfactu
scenario
novaccin
vaccin
impact
assess
quantifi
effect
number
vaccin
need
avert
one
infect
one
advers
diseas
outcom
ratio
number
vaccin
rel
avert
outcom
latter
measur
essenti
costeffect
cost
includ
yet
avail
vaccin
assum
elicit
protect
year
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
two
vaccin
program
scenario
consid
program
assum
vaccin
introduc
absenc
socialdistanc
intervent
purpos
vaccin
replac
intervent
first
program
scenario
assum
vaccin
introduct
scaleup
coverag
epidem
onset
scenario
relev
assess
impact
vaccin
futur
introduct
countri
epidem
contain
low
level
china
scenario
also
relev
assess
maximum
potenti
impact
vaccin
regardless
current
epidem
statu
second
program
scenario
assum
vaccin
introduct
epidem
exponenti
growth
phase
scaleup
coverag
within
one
month
incid
new
infect
assess
variou
level
determin
minimum
efficaci
need
fulli
control
infect
incid
also
assess
scenario
vaccin
introduc
socialdistanc
intervent
estim
level
social
distanc
need
complement
vaccin
control
infect
incid
assess
anoth
scenario
vaccin
increas
social
contact
behavior
compens
assess
consequ
vaccin
impact
lastli
deriv
estim
likelihood
occurr
major
outbreak
follow
infect
introduct
vaccin
infectionfre
popul
section
sm
multivari
uncertainti
analysi
conduct
determin
rang
uncertainti
around
model
predict
use
fivehundr
model
run
run
latin
hypercub
sampl
appli
select
natur
histori
diseas
progress
paramet
valu
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
impact
infect
incid
reduc
peak
incid
sever
critic
diseas
death
figur
cumul
incid
latter
three
outcom
figur
sm
second
scenario
figur
figur
sm
vaccin
rapidli
scale
coverag
exponenti
growth
phase
epidem
peak
earlier
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
larg
number
vaccin
need
avert
one
infect
one
advers
outcom
note
minor
differ
effect
time
instanc
initi
phase
epidem
priorit
year
age
slightli
effect
priorit
year
age
figur
sm
meanwhil
toward
end
epidem
cycl
invers
true
figur
illustr
gain
effect
vaccin
fulli
control
epidem
figur
sm
show
impact
vaccin
supplement
socialdistanc
intervent
reduc
contact
rate
less
reduct
contact
rate
would
suffici
fulli
control
epidem
vaccin
individu
may
increas
contact
rate
percept
protect
figur
show
consequ
behavior
compens
increas
contact
rate
among
vaccin
lower
reduct
cumul
incid
increas
contact
rate
nullifi
impact
vaccin
reduc
incid
figur
report
probabl
occurr
major
outbreak
vari
level
vaccin
efficaci
gradual
decreas
note
increas
efficaci
acceler
close
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
effect
enhanc
priorit
vaccin
year
age
optim
reduct
diseas
case
death
figur
convers
priorit
children
least
effect
lower
risk
develop
advers
outcom
figur
said
priorit
vaccin
singl
age
group
regardless
age
group
overal
lower
effect
extend
vaccin
age
groupsvaccin
one
age
group
reduc
reproduct
number
r
margin
wherea
vaccin
age
group
reduc
r
epidem
domain
small
reduct
r
substanti
impact
epidem
size
figur
sm
also
figur
versu
figur
consequ
rollout
strategi
initi
priorit
individu
year
age
increment
cover
younger
age
cohort
eventu
entir
popul
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
vaccin
also
reduc
likelihood
major
outbreak
follow
viru
introductionreintroduct
popul
figur
vaccin
infect
transmiss
chain
may
sustain
regardless
number
viru
introduct
concern
howev
potenti
increas
social
contact
rate
among
vaccin
cycl
assum
long
durat
vaccin
protect
year
limit
impact
predict
one
epidem
cycl
provid
durat
vaccin
protect
greater
one
year
despit
limit
model
complex
enough
factor
differ
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
key
vaccin
product
characterist
also
parsimoni
enough
tailor
natur
avail
data
model
also
gener
result
valid
wide
rang
model
assumpt
world
popul
remain
suscept
need
impos
disrupt
socialdistanc
intervent
vaccin
reliabl
intervent
longterm
find
show
even
partiallyefficaci
vaccin
provid
fundament
solut
pandem
high
costeffect
vaccin
impact
costeffect
depend
efficaci
prevent
infect
enhanc
vaccin
still
acquir
infect
reduc
infecti
durat
infect
diseas
sever
vaccin
develop
thu
assess
primari
endpoint
reduct
acquisit
also
outcom
andor
proxi
biomark
includ
reduct
viral
load
diseas
outcom
speed
infect
clearanc
vaccin
unvaccin
total
primari
secondari
endpoint
may
prove
critic
licensur
process
decisionmak
vaccin
impact
introduc
popul
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
tabl
key
vaccin
product
characterist
use
assess
impact
vaccin
proport
increas
social
contact
rate
reduc
social
distanc
among
vaccin
compar
unvaccin
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
new
critic
diseas
case
new
death
scenario
assum
vaccin
scaleup
coverag
epidem
onset
durat
vaccin
protect
year
impact
assess
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
new
critic
diseas
case
new
death
scenario
assum
vaccin
introduct
exponenti
growth
phase
epidem
scaleup
coverag
within
one
month
durat
vaccin
protect
year
impact
assess
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
figur
effect
agegroup
priorit
use
vaccin
ve
number
vaccin
need
avert
one
infect
b
one
sever
diseas
case
c
one
critic
diseas
case
one
death
priorit
differ
age
group
vaccin
scenario
assum
vaccin
scaleup
coverag
epidem
onset
durat
vaccin
protect
year
effect
assess
end
epidem
cycl
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
scenario
assum
vaccin
scaleup
coverag
epidem
onset
durat
vaccin
protect
year
measur
assess
end
epidem
cycl
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
figur
impact
vaccin
reduc
adher
social
distanc
vaccin
figur
show
impact
vari
level
behavior
compens
postvaccin
vaccineinduc
reduct
cumul
number
new
infect
end
epidem
cycl
scenario
assum
vaccin
scaleup
coverag
epidem
onset
ve
durat
vaccin
protect
year
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
scenario
assum
vaccin
scaleup
coverag
epidem
onset
durat
vaccin
protect
year
figur
includ
result
p
efficaci
impact
probabl
occurr
major
outbreak
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
declar
compet
interest
public
made
possibl
nprp
grant
number
nprp
grant
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
figur
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
vaccin
popul
age
year
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
subsequ
age
group
follow
set
equat
use
unvaccin
popul
age
year
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
definit
popul
variabl
symbol
use
equat
tabl
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
h
matrix
provid
probabl
individu
age
group
mix
individu
age
group
regardless
vaccin
statu
mix
matrix
given
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
age
e
mix
fulli
assort
individu
mix
member
age
group
input
paramet
model
chosen
base
current
empir
data
natur
histori
epidemiolog
paramet
valu
list
tabl
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
use
second
gener
matrix
method
describ
heffernan
et
al
basic
reproduct
number
absenc
vaccin
given
w
proport
popul
age
group
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doiorg
meanwhil
basic
reproduct
number
presenc
vaccin
given
base
whittl
method
construct
bailey
ratio
probabl
major
outbreak
deriv
probabl
fraction
suscept
individu
becom
infect
specif
chosen
level
final
attack
rate
defin
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
meanwhil
case
vaccin
fraction
popul
probabl
major
outbreak
given
follow
three
case
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
probabl
major
outbreak
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
figur
tempor
evolut
effect
agegroup
priorit
use
vaccin
ve
number
vaccin
need
avert
one
infect
b
one
death
priorit
individu
age
year
scenario
assum
vaccin
scaleup
coverag
epidem
onset
durat
vaccin
protect
year
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
figur
impact
socialdistanc
intervent
reduc
contact
rate
popul
cumul
number
new
infect
introduc
supplement
impact
vaccin
efficaci
reduc
suscept
ve
scenario
assum
vaccin
scaleup
coverag
epidem
onset
durat
vaccin
protect
year
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
figur
uncertainti
analysi
model
predict
mean
cumul
number
new
infect
associ
uncertainti
interv
ui
variou
level
vaccin
efficaci
reduc
suscept
ve
gener
simul
run
scenario
assum
vaccin
scaleup
coverag
epidem
onset
durat
vaccin
protect
year
solid
black
line
dash
line
shade
show
respect
mean
uncertainti
interv
individu
estim
cumul
number
new
infect
across
uncertainti
run
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
figur
vaccin
effect
agegroup
priorit
reproduct
number
model
predict
sar
attack
rate
variou
level
indic
also
impact
priorit
year
age
vaccin
vaccin
age
group
blue
dasheddot
line
show
modelpredict
attack
rate
variou
level
blue
red
green
star
show
respect
modelpredict
attack
rate
absenc
vaccin
priorit
vaccin
coverag
year
age
extend
vaccin
coverag
age
group
figur
highlight
effect
vaccin
number
vaccin
need
avert
one
infect
depend
posit
curvepriorit
vaccin
singl
age
group
regardless
age
group
overal
lower
effect
extend
vaccin
age
group
reason
vaccin
one
age
group
reduc
margin
wherea
vaccin
age
group
reduc
epidem
domain
small
reduct
substanti
impact
epidem
size
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
figur
impact
vari
level
vaccin
efficaci
reduc
suscept
ve
cumul
number
new
infect
reproduct
number
scenario
assum
vaccin
scaleup
coverag
epidem
onset
durat
vaccin
protect
year
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
